Although our new method to quantify EGFR expression using cetuximab requires further validation as a biomarker of the efficacy of anti-EGFR therapy, our results suggest that EGFR expression levels correlate with sensitivity of CRC to cetuximab. The gene discussed is EGFR; the disease is colorectal carcinoma.